Related Experiment Video

Updated: Aug 21, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Management of meningococcemia

Jasjit Singh1, Antonio C Arrieta

  • 1Division of Pediatric Infectious Diseases, Children's Hospital of Orange County, 455 South Main Street, Orange, CA 92868, USA. jsingh@choc.org

Indian Journal of Pediatrics
|November 9, 2004
PubMed

Insights

Meningococcemia, a severe disease, leads to significant illness and death globally. This review covers its causes, symptoms, treatments, and prevention, including genetic factors and new vaccines.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • Meningococcemia is a severe bacterial infection with high global morbidity and mortality.
  • It often presents as fulminant disease, requiring urgent medical attention.
  • Understanding its epidemiology and pathogenesis is crucial for effective control.

Purpose of the Study:

  • To provide a comprehensive review of meningococcemia.
  • To discuss recent advances in understanding genetic predispositions.
  • To update on novel therapeutic strategies and vaccine development.

Main Methods:

  • Literature review of background, pathophysiology, and clinical manifestations.
  • Analysis of current treatment modalities, including adjunctive therapies.
  • Evaluation of prevention strategies, focusing on conjugate vaccines and public health aspects.

Main Results:

  • Meningococcemia presents with diverse clinical manifestations and pathophysiology.
  • Genetic factors play a role in susceptibility to invasive meningococcal disease.
  • Monoclonal antibodies and activated protein C show potential as adjunctive treatments.
  • Conjugate vaccines are advancing in development and implementation.

Conclusions:

  • Effective management of meningococcemia requires a multifaceted approach.
  • Continued research into genetic susceptibility and novel therapies is essential.
  • Vaccine development and public health initiatives are key to reducing disease burden.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.